GlobeNewswire

Vaisala's Financial Statement Release January–December 2020 to be published on February 19, 2021

Share

Vaisala Corporation
Press release
February 2, 2021 at 1:00 p.m. (EET)

Vaisala's Financial Statement Release January–December 2020 to be published on February 19, 2021

Vaisala Corporation will publish its Financial Statement Release January–December 2020 on Friday, February 19, 2021 at about 9:00 a.m. (Finnish time). The report will be available at vaisala.com/investors. The President and CEO's presentation will be published by 11:00 a.m. on the same day at vaisala.com/investors.

Conference call
An English-language conference call for analysts, investors and media will be held on the same day starting at 11:00 a.m. (Finnish time). Numbers for conference call, during which questions may be presented, are:

Finland: +358 9 8171 0310
UK: +44 33 3300 0804
Sweden: +46 8 5664 2651
US: +1 63 1913 1422

PIN: 19622715#

Audiocast
The presentation by Kai Öistämö, President and CEO, can also be followed through a live audiocast at vaisala.com/investors starting at 11:00 a.m. A recording will be published at the same address by 1:00 p.m.

More information
Paula Liimatta, Business Controller and Head of Investor Relations
Tel. +358 40 580 3521

Distribution
Key media
vaisala.com

Vaisala is a global leader in environmental and industrial measurement. Building on over 80 years of experience, Vaisala provides observations for a better world. We are a reliable partner for customers around the world, offering a comprehensive range of innovative observation and measurement products and services. Headquartered in Finland, Vaisala employs approximately 1,900 professionals worldwide and is listed on the Nasdaq Helsinki stock exchange.  vaisala.com  twitter.com/VaisalaGroup


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Norsk Hydro: Invitation to Investor presentation - Hydro agrees to sell Rolling business area to KPS Capital Partners5.3.2021 07:31:00 CETPress release

President & CEO, Hilde Merete Aasheim, will present the transaction by an audio webcast and a conference call, in English, at 09:00 CET today, Friday 5 March. In order to listen to the presentation, please join the audio webcast. There will be a Q&A session directly after the presentation. If you would like to ask questions, you need to join the conference call before end of the presentation. Please see details below. It will not be possible to ask questions on the audio webcast. To join the conference call, please use the below “Click to Join” link 5-10 minutes prior to start time. You will be asked to enter your phone number and registration details. The Event Conferencing system will call you on the phone number you provide and place you into the event. Please note that the “Click to Join” link becomes active 15 minutes prior to the scheduled start time. Please use the “Click to Join” option for the easiest way to join the conference call. Click to Join Call 09:00 CET >> As an alter

Norsk Hydro: Invitasjon til Investorpresentasjon - Hydro selger forretningsområdet Rolling til KPS Capital Partners5.3.2021 07:31:00 CETPressemelding

Konsernsjef Hilde Merete Aasheim vil presentere transaksjonen i dag, fredag 5. mars kl. 09.00 (norsk tid) via audio webcast og telefonkonferanse. Presentasjonen kan følges via audio webcast. Det vil være mulig å stille spørsmål rett etter presentasjonen. For å stille spørsmål må du være koblet på telefonkonferansen før presentasjonen er ferdig. Se detaljer nedenfor. Det vil ikke være mulig å stille spørsmål via audio webcast. Du melder deg på telefonkonferansen ved å klikke på lenken “Click to Join“ 5-10 minutter før start. Du må oppgi telefonnummer og registreringsdetaljer. Konferansesystemet vil ringe tilbake på det oppgitte telefonnummeret og koble deg til konferansen. “Click to Join“-lenken vil være aktiv fra 15 minutter før planlagt start. Vennligst bruk “Click to Join“ for den enkleste måten å delta på telefonkonferansen. Click to Join Call 09:00 CET >> Alternativt kan du ringe numrene nedenfor for telefonkonferansen: Norge +47 2100 2613 UK +44 (0)330 336 9104 USA +1 323-794-2442

Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million5.3.2021 07:30:00 CETPress release

Energy and aluminium company Norsk Hydro ASA has entered into an agreement to sell its Rolling business to KPS Capital Partners for EUR 1,380 million on an enterprise value basis. A major step on Hydro's agenda to improve profitability and drive sustainability. The transaction includes seven plants, one R&D center, global sales offices, and around 5,000 employees of which 650 employees in Norway and the remaining mainly in Germany. “Hydro launched a strategic review of our Rolling business area in 2019, along with other strategic measures towards profitability and sustainability. We have now concluded, and our Rolling business will continue its development under new ownership. This is a good solution for both Hydro and for the employees in Rolling, who will continue their efforts and continued growth in a new, dedicated downstream company,” says Hydro President and CEO Hilde Merete Aasheim. “Hydro’s ambition is to lift profitability and drive sustainability, creating value for all stak

Norsk Hydro: Hydro selger forretningsområdet Rolling til KPS Capital Partners for 1.380 millioner euro5.3.2021 07:30:00 CETPressemelding

Energi- og aluminiumselskapet Norsk Hydro ASA har inngått en avtale om å selge forretningsområdet Rolling til KPS Capital Partners for 1.380 millioner euro Enterprise Value. Dette er et stort skritt videre for Hydros agenda om å løfte lønnsomheten og fremme bærekraft. Transaksjonen omfatter syv anlegg, ett FoU-senter og internasjonale salgskontorer, i tillegg til rundt 5 000 ansatte hvorav 650 i Norge og resterende hovedsakelig i Tyskland. – Hydro startet en strategisk gjennomgang av forretningsområdet Rolling i 2019, sammen med andre strategiske tiltak for økt lønnsomhet og bærekraft. Vi har nå konkludert, og forretningsområdet Rolling vil fortsette sin utvikling under nytt eierskap. Dette er en god løsning, både for Hydro og for de ansatte i Rolling, som vil fortsette arbeidet og vokse videre i et nytt, rendyrket nedstrømselskap, sier Hydros konsernsjef, Hilde Merete Aasheim. – Hydros ambisjon er å løfte lønnsomheten og fremme bærekraft, og skape verdier for alle interessegrupper. Sa

Heijmans and AM join forces in Feyenoord City Rotterdam5.3.2021 07:30:00 CETPress release

Heijmans and project developer AM have joined forces in the Feyenoord City development consortium, which aims to develop and realise homes and commercial and social amenities in Rotterdam South. This collaboration is a significant step towards the integrated development of the area. Homes and commercial real estate The Heijmans-AM consortium will be working closely with Stigam (Stichting Gebiedsontwikkeling aan de Maas – the foundation set up to oversee the area development). Stigam is responsible for the land development. The Rotterdam South area development entered a new phase following the Rotterdam city council’s adoption of the zoning plan in late 2020. Feyenoord City will include the new stadium that will be developed by Stadion Feijenoord N.V. Around this new stadium, the Heijmans-AM consortium will develop an attractive city district that will include homes, a hotel, food & beverage outlets and shops. The Feyenoord City Masterplan gives the room to develop a total of around 3,7

ObsEva Announces Year End 2020 Financial Results and Business Update5.3.2021 07:00:00 CETPress release

-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept- -Actively pursuing new indications and partnerships to maximize value of pipeline candidates- GENEVA, Switzerland and BOSTON, MA – March 5, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the year ended December 31, 2020 and provided a business update. “2020 was a critical year for ObsEva as it marked the beginning of our transformation from a clinical stage company to one preparing for regulatory approvals and commercialization,” said Brian O’Callaghan, CEO of ObsEva. “The clinical and regulatory achievements of 2

Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition5.3.2021 07:00:00 CETPress release

Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threateningIn a global study, Actemra/RoActemra reduced the rate of progressive loss of lung function in people with SSc-ILD compared to placeboThe U.S. Food and Drug Administration previously granted Priority Review designation to Actemra/RoActemra for the treatment of SSc-ILD Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for